Patientory Wallet launches telehealth service for GLP-1, raises additional funding
Over the past decade, the United States has been actively contending with obesity rates, with almost 40% of US adults being obese and a further 31.5% being overweight. To combat rising rates and promote healthier lifestyles, Patientory – a telehealth service and healthcare data startup – is creating personalized healthcare plans for individuals.
Patientory has announced the launch of its new telehealth service, which will offer customized coaching that incentivizes health habits, alongside GLP-1 prescriptions, like Semaglutide. In previous years, Patientory gained attention for making waves in the Web 3 community, providing a decentralized application that used an individual’s data to contribute to more effective health analysis.
A core part of Patientory’s offering was the ability for participants in clinical research to get reward-based payments, helping to further incentivize participation in medical studies. Their new weight-loss program will offer users that meet eligibility criteria a customized prescription plan, including:
- Ongoing support
- A medical telehealth consultation
- Supply of Semaglutide medication
Patientory aims to elevate health dara democratization by utilizing its decentralized applications like the Digital Health Data Wallet. Commenting on their vision, the Co-Founder and Managing Partner of Corridor Ventures, Kwamena Aidoo, commented that “Connecting wearable device and electronic health records data has the potential to transform clinical research insights and evolve the way health and wellness care is administered across the globe.”
They continue, suggesting that “Patientory sits at the forefront of this movement. When you think about this in the broader context of our rapidly changing technological landscape, it is hard not to get excited.”
For customers who are interested in getting started with Patientory’s new offering, downloading the Patientory Health Data Wallet is the place to begin. By verifying a user’s BMI on the app, they can check if they fulfill the eligibility criteria and gain access to the Semaglutide GLP-1 prescription.
Semaglutide is a glucagon-like peptide-1 reception agonist, mimicking the GLP-1 hormone, which is typically released in response to eating. The GLP-1 hormone stimulates insulin production in the body to regulate blood glucose levels. Previous clinical trials have suggested that Semaglutide can be an effective part of promoting weight loss.
The recent announcement comes in light of Patientory being named a “2024 Health Equity Business Accelerator Participant”, just after their early-funding stage generated investments of over $325,000.
Patientory’s new weight-loss offering will become available from February 7th, 2024.